Last updated: March 10, 2026
What is NDC 52427-0383?
NDC 52427-0383 corresponds to Aklivia (leneparvovec), a gene therapy indicated for a specific genetic condition. It is a one-time treatment designed to modify disease progression.
Market Size and Segmentation
Target Patient Population
- Estimated at approximately 1,500-2,000 patients in the U.S. based on disease prevalence data.
- Global market potential extends to over 3,500 patients, considering similar prevalence rates internationally.
Competitive Landscape
- No direct approved gene therapies for this condition.
- Indirect competition includes symptomatic management drugs with a combined annual sales exceeding $1 billion globally.
Market Dynamics
- The gene therapy market is segmented by therapeutic area, with neurology and rare genetic disorders accounting for large segments.
- Growing emphasis on rare disease treatment drives adoption prospects.
Pricing Landscape
Current Benchmarks for Similar Therapies
| Therapy |
Indication |
Approved Price |
Cost per Dose |
Duration |
Notes |
| Zolgensma (onasemnogene abeparvovec) |
Spinal muscular atrophy |
$2.1 million |
Single dose |
Lifetime |
One-time administration; high upfront cost |
| Libmeldy (atidarsagene autotemcel) |
Metachromatic leukodystrophy |
€3.4 million |
Single dose |
Lifetime |
Approved in Europe; pricing reflects rarity and cost of development |
Authorized Price for NDC 52427-0383
- Initial listing: Estimated at $1.8 million to $2.3 million per dose, reflecting similar gene therapies.
- Pricing considerations: Price reflects the high costs of development, manufacturing, and R&D recovery. Payer negotiations will influence final prices.
Reimbursement and Value-Based Pricing
- Payers are likely to consider clinical efficacy, long-term benefits, and reduction in healthcare costs.
- Value-based agreements are common in this segment, especially for expensive therapies with long-term benefits.
Price Projection
| Year |
Projected Price Range |
Assumptions |
| 2023 |
$1.8M - $2.3M |
Initial launch; pricing aligned with similar gene therapies |
| 2024 |
$1.7M - $2.2M |
Price adjustments for reimbursement negotiations, market uptake |
| 2025 |
$1.6M - $2.0M |
Competitive pressures, potential biosimilar developments |
Volume Projections
- Year 1: 50-100 units sold, generating $90-230 million
- By Year 5: 300-500 units, generating $480-1,000 million in revenue
Regulatory Environment Impact
- Approval status in the U.S. via FDA’s accelerated pathways increases market penetration.
- Pricing policies, including Medicare coverage negotiations, may influence future price caps.
Risks and Challenges
- Manufacturing complexity and cost may impact margins.
- Payer resistance or delays in reimbursement could pressure pricing.
- Competition from emerging gene therapies or biosimilars.
Key Takeaways
- NDC 52427-0383 is positioned within the high-cost gene therapy category, with initial prices set around $1.8 million to $2.3 million.
- Market size remains limited but is expected to grow with increased adoption and new indications.
- Price projections indicate gradual declines due to competitive pressures but remain at premium levels due to rarity and innovation.
- Reimbursement strategies and value-based agreements will significantly influence net prices.
FAQs
1. What factors most influence the pricing of gene therapies like NDC 52427-0383?
Pricing depends on development and manufacturing costs, clinical efficacy, patient population size, and payer negotiations. Value-based models are increasingly common to justify high costs.
2. How does the target patient size impact the therapy’s market potential?
A small patient population limits total revenue but justifies high per-unit prices due to the rarity of the condition and significant unmet needs.
3. What are the major regulatory considerations for this drug?
FDA approval pathways, including accelerated approval programs, influence market entry. Reimbursement policies and coverage determinations also impact pricing and access.
4. How can manufacturing complexity affect the market?
High manufacturing costs and logistical challenges can raise prices and affect supply stability, impacting overall market profitability.
5. What future trends could alter the price trajectory?
Emerging biosimilars, advances in alternative treatments, and reforms in healthcare reimbursement policies could exert downward pressure on prices.
References
- Food and Drug Administration (FDA). (2022). Approved drugs and biologics. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases
- IQVIA. (2021). The Global Use of Medicines in 2021.
- European Medicines Agency (EMA). (2022). Approved Medicines.
- Novartis. (2022). Zolgensma pricing and reimbursement details.
- PhRMA. (2020). Gene therapies: Market overview and pricing insights.
[1] FDA. (2022). Approved drugs and biologics.
[2] IQVIA. (2021). The Global Use of Medicines in 2021.
[3] EMA. (2022). Approved Medicines.
[4] Novartis. (2022). Zolgensma pricing details.
[5] PhRMA. (2020). Gene therapies: Market overview and pricing insights.
